Exploring Repurposed Medicines in Cancer Care: The Ivermectin and Fenbendazole Protocol
The ivermectin fenbendazole protocol for cancer is generating significant interest in integrative oncology circles around the world. Indeed, a compelling presentation by Dr. Amir Farid Isahak offers a thorough and accessible overview of this emerging approach. As a result, it is well worth exploring what this may mean for people who are seeking holistic and integrative approaches to cancer support.
Who Is Dr. Amir Farid Isahak?
Dr. Amir Farid Isahak is a senior medical consultant with more than 45 years of practice. Although he is a retired Ob/Gyn, he continues to work in holistic integrative medicine with a focus on anti-ageing and chronic lifestyle diseases. His journey into this space began during the COVID-19 pandemic, when he became a prominent advocate for ivermectin. In addition, he has since extended his work to explore its potential — alongside fenbendazole and mebendazole — in supporting people living with cancer, particularly those who have not responded to conventional therapies or who are seeking complementary approaches.
What Are Ivermectin, Fenbendazole, and Mebendazole?
Ivermectin, fenbendazole, and mebendazole are antiparasitic (deworming) medications that humans and animals have used safely for decades. In recent years, however, researchers and clinicians around the world have been investigating whether these widely available, low-cost medicines may also have a role in cancer treatment. Moreover, interest has grown particularly among people with advanced cancers who have exhausted conventional options, or who are looking to complement their existing care with integrative strategies.
A Landmark Peer-Reviewed Publication
In September 2024, a significant milestone was reached. Specifically, the Journal of Orthomolecular Medicine (Vol. 39, No. 3) published the first-ever peer-reviewed protocol for the use of these three drugs in cancer care. Lead researchers Ilyes Baghli and Pierrick Martinez authored the paper, alongside Dr. Paul Marik of the Frontline COVID-19 Critical Care Alliance (FLCCC) and 12 co-authors from institutions across North America, Europe, and Asia.
Importantly, the research draws on insights from molecular biology, pharmacology, and clinical studies. Furthermore, the authors propose a hybrid orthomolecular protocol built around the mitochondrial-stem cell connection (MSCC) theory — the concept that cancer may originate from impaired energy metabolism in stem cells. For many in the integrative health community, therefore, this publication marks an important step toward formal recognition of a field of inquiry that patient communities and holistic medicine circles have long discussed.
The full paper is available to read at: https://isom.ca/article/targeting-the-mitochondrial-stem-cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
What Does Dr. Amir’s Presentation Cover?
Dr. Amir’s presentation on the ivermectin fenbendazole protocol for cancer is both educational and practical. In particular, he covers:
- A brief history of ivermectin and fenbendazole/mebendazole
- How these three deworming drugs came to be repurposed for cancer research
- Results from patient testimonies, case reports, and his own clinical experience
- Detailed protocols for using ivermectin and fenbendazole/mebendazole in cancer care
- Complementary treatments and supplements commonly used alongside the protocol
- His own personal protocol
Furthermore, whether you are new to this topic or already researching your options, Dr. Amir’s presentation on the ivermectin fenbendazole protocol for cancer is a valuable educational resource for anyone in the cancer community.
Watch the Presentation
Watch Dr. Amir Farid Isahak’s full presentation on the ivermectin fenbendazole protocol for cancer below:
An Important Note
While this research is promising, it is important to note that ivermectin, fenbendazole, and mebendazole are not currently approved for the treatment of cancer in humans. Nevertheless, CanSurvive shares this article for educational purposes only, as part of our commitment to keeping our community informed about emerging conversations in integrative and holistic cancer care. As always, we encourage members to discuss any new or complementary treatment approaches with their healthcare team before making any changes to their care plan.
The information in this article is for educational purposes only and does not constitute medical advice. Always consult your qualified healthcare provider before beginning any new treatment or supplement protocol.
Source: Baghli I, et al. (2024). Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. Journal of Orthomolecular Medicine, 39(3). Published 19 September 2024. https://isom.ca/article/targeting-the-mitochondrial-stem-cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
